Italia markets closed

180 Life Sciences Corp. (ATNF)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,1600-0,1800 (-7,69%)
Alla chiusura: 04:00PM EDT
2,1200 -0,04 (-1,85%)
Dopo ore: 06:46PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,3400
Aperto2,2400
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,1072 - 2,3480
Intervallo di 52 settimane1,8050 - 27,9300
Volume20.951
Media Volume92.223
Capitalizzazione1,842M
Beta (5 anni mensile)0,44
Rapporto PE (ttm)N/D
EPS (ttm)-52,5900
Prossima data utili13 mag 2024 - 17 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

    PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately e

  • GlobeNewswire

    180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

    PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing of a public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants will be immediately exercisable at an ex

  • GlobeNewswire

    180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

    PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“Pharmacokinetic” or “PK”) study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally. The PK study will seek to determine